References
- Sturgeon CM, Berger P, Bidart JM et al. Differences in recognition of the 1st WHO international reference reagents for hCG-related isoforms by diagnostic immunoassays for human chorionic gonadotropin. Clin. Chem.55, 1484–1491 (2009).
- Stenman UH, Alfthan H, Hotakainen K. Human chorionic gonadotropin in cancer. Clin. Biochem.37, 549–561 (2004).
- Lempiainen A, Stenman UH, Blomqvist C, Hotakainen K. Free β-subunit of human chorionic gonadotropin in serum is a diagnostically sensitive marker of seminomatous testicular cancer. Clin. Chem.54, 1840–1843 (2008).
- Sturgeon CM, Hoffman BR, Chan DW et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin. Chem.54, e1–e10 (2008).
- Ballieux BE, Weijl NI, Gelderblom H, van Pelt J, Osanto S. False-positive serum human chorionic gonadotropin (hCG) in a male patient with a malignant germ cell tumor of the testis: a case report and review of the literature. Oncologist13(11), 1149–1154 (2008).
- Gilligan TD, Seidenfeld J, Basch EM et al. American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J. Clin. Oncol.28, 3388–3404 (2010).
- International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J. Clin. Oncol.15, 594–603 (1997).
- Carver BS, Motzer RJ, Kondagunta GV, Sogani PG, Sheinfeld J. Late relapse of testicular germ cell tumors. Urol. Oncol.23, 441–445 (2005).
- Chung P, Parker C, Panzarella T et al. Surveillance in stage I testicular seminoma – risk of late relapse. Can. J. Urol.9, 1637–1640 (2002).